

Supplementary Table 1

| | First line treatment in the CT only group | CRT + adjuvant CT | Neo-CT + CRT | CRT only |
|--|--|----------------------|-----------------|-----------|
| | Cases (n) | Cases (n) | Cases (n) | Cases (n) |
| Chemotherapy regimens used in first line, n=30 | | | | |
| <i>Carboplatin + paclitaxel</i> | 4 | 0 | 3 | 0 |
| <i>Carboplatin + paclitaxel + bevacizumab</i> | 4 | 0 | 3 | 0 |
| <i>Cisplatin + gemcitabine</i> | 0 | 3 | 0 | 0 |
| <i>Carboplatin + paclitaxel + bevacizumab + pembrolizumab</i> | 1 | 0 | 0 | 0 |
| <i>Cisplatin + topotecan</i> | 1 | 2 | 0 | 0 |
| <i>Cisplatin</i> | 0 | 0 | 0 | 9 |
| Immunotherapy used in second treatment line, n=11 | | | | |
| <i>Pembrolizumab (second line)</i> | 1 | 1 | 1 | 2 |
| <i>Clinical trial - MK 7684 Pembrolizumab + vibostolimab</i> | 4 | 0 | 0 | 0 |
| <i>Clinical trial - NeoTx (durvalumab+ naptumumab)</i> | 1 | 0 | 0 | 0 |
| <i>Clinical trial - MK 58909 (pembrolizumab)</i> | 0 | 0 | 1 | 0 |
| Immunotherapy used advanced treatment line, n=3 | | | | |
| <i>Pembrolizumab (second line)</i> | 0 | 1 | 0 | 0 |
| <i>Clinical trial - MK 7684 (pembrolizumab + vibostolimab)</i> | 0 | 1 | 0 | 0 |
| <i>Nivolumab</i> | 1 | 0 | 0 | 0 |

Abbreviations: Chemotherapy (CT), Chemoradiation (CRT), Number (n), Neoadjuvant chemotherapy (Neo-CT)